Kyverna Therapeutics, Inc. (NASDAQ: KYTX)

This lawsuit is for anyone who acquired securities in Kyverna Therapeutics, Inc. (NASDAQ: KYTX) from February 7, 2024 through December 9, 2024.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, in the Prospectus the Company’s IPO, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by withholding information the Company had regarding adverse clinical data on its lupus nephritis drug, KYV-101.

On June 14, 2024, Kyverna provided an update on its lupus nephritis drug, KYV-101, and published an investor presentation disclosing adverse data regarding one of its clinical trials, despite having previously touted patient improvement. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume and remained below the IPO price on the date of this lawsuit.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Kyverna Therapeutics, Inc. (NASDAQ: KYTX) from February 7, 2024 through December 9, 2024 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.